Listed by the USPTO as RAHMANI, NILOOFAR
Tech Center 1600 • Art Units: 1621 1625 1634 1691
This examiner grants 78% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18694597 | INSECT, ACARINA AND NEMATODE PEST CONTROL | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18722233 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18711986 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | Non-Final OA | Rgenta Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy77.6% of resolved applications examined by Niloofar Rahmani were allowed (1,146 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is -2.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Niloofar Rahmani took 722 days on average from filing to allowance.
Niloofar Rahmani examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
